For results they can feel, prescribe DUPIXENT to target type 2 inflammation, treat OCS-dependent and type 2 asthma patients, and transform their lives with rapid, sustained control... Choose DUPIXENT to open up a world beyond their asthma symptoms.
-
IL-4 and IL-13, two key and central drivers of type 2 inflammation
-
TREAT OCS-dependent patients3 & Type 2 asthma patients
- TRANSFORM patient lives beyond symptoms
- 86% of patients reduced or eliminated OCS while maintaining asthma control3,a
- Up to 550 mL improvement in FEV16,b
- Up to 75% exacerbation reduction6,c
MAT-BH-2400019/V1/Jan 2024